[Cis-diamminedichloroplatinum(II) chemotherapy in advanced pancreatic carcinoma].
The effect of cis-diamminedichloro platinum (II) (CDDP) was evaluated in 14 patients with advanced pancreatic carcinoma. Prior chemotherapy was done in 7 cases and the remaining 7 were fresh cases. The drug was given at a dose of 80 mg/m2 I.V. every 3 weeks, with hydration and mannitol diuresis. Four cases out of 14 showed no change, while the remaining 10 cases showed progressive disease. The response rate was 0%. Most of the patients who showed myelosuppression had received prior chemotherapy. Non-hematologic toxicity occurred in 9 patients (64%) and consisted of nausea in 9, vomiting in 7 and anorexia in 9. Values of serum creatinine and BUN were transiently elevated.
Tajiri
H
H
Dept. of Internal Medicine, National Cancer Center Hospital.
Yoshimori
M
M
Hijikata
A
A
Nakamura
K
K
Ohkura
H
H
Okazaki
N
N
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D001806:Blood Urea Nitrogen; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D002945:Cisplatin